Top 7 Stocks to BUY NOW (During the Dip)
Summary
Kuran presents a detailed analysis of seven stocks and one ETF that Kuran believes are well-positioned for growth through 2026. Kuran emphasizes that while major AI players like Nvidia and Google have seen recent pullbacks, this creates an opening for other technological sectors to shine. Kuran advocates for a long-term 'buy and hold' strategy to weather the inherent volatility of growth investing.
Mentioned Stocks
Reasoning: Kuran is very positive on the long-term prospects of the space economy and Rocket Lab's pivot to space systems. However, Kuran is explicitly waiting for the $8 billion Iridium acquisition to close before making a personal investment. Kuran notes the stock is currently 50% overvalued based on traditional models and carries dilution risks.
Reasoning: Kuran is bullish on Zscaler due to the rising demand for Zero Trust architecture to counter AI-driven cyber threats. Kuran currently holds 82 shares and highlights that the company is on the verge of profitability. Kuran points to potential S&P 500 inclusion as a major catalyst for the stock price.
Reasoning: Kuran identifies Datadog as a leader in observability, which is necessary for AI to function without 'hallucinating.' Kuran holds 146 shares and highlights the 40% annual revenue growth and 120% net retention rate. Kuran views the company as a high-conviction growth play despite a premium valuation.
Reasoning: Kuran describes Cloudflare as one of the most innovative companies in the world, powering 20% of the internet. Kuran holds 172 shares and believes its infrastructure is essential for the transition to an 'agentic internet.' Despite being 40% overvalued by Kuran's estimation, Kuran argues that high-quality growth stocks often trade at all-time highs.
Reasoning: Kuran recommends this ETF as a diversified way to gain exposure to the growing space industry. Kuran explains that it includes SpaceX and Rocket Lab along with satellite and defense firms. While it is volatile and has a 0.5% expense ratio, Kuran sees it as a strong thematic play.
Reasoning: Kuran views Novanta as a strategically well-positioned play in robotics and MedTech. While Kuran owns 19 shares, Kuran notes it is not a core portfolio component due to its status as a smaller, more volatile company. Kuran considers it fairly valued at present but mentions risks regarding China and high dependency on the medical market.
Reasoning: Kuran explicitly states that Kuran recently bought more shares of Kaspi. Kuran highlights its 40% undervaluation and its status as a highly profitable 'super-app' in Kazakhstan. Kuran is particularly attracted by the 7%+ combined yield from dividends and stock buybacks.